학술논문
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Document Type
Article
Author
Abou-Alfa, Ghassan K; Macarulla, Teresa; Javle, Milind M; Kelley, Robin K; Lubner, Sam J; Adeva, Jorge; Cleary, James M; Catenacci, Daniel V; Borad, Mitesh J; Bridgewater, John; Harris, William P; Murphy, Adrian G; Oh, Do-Youn; Whisenant, Jonathan; Lowery, Maeve A; Goyal, Lipika; Shroff, Rachna T; El-Khoueiry, Anthony B; Fan, Bin; Wu, Bin; Chamberlain, Christina X; Jiang, Liewen; Gliser, Camelia; Pandya, Shuchi S; Valle, Juan W; Zhu, Andrew X
Source
In The Lancet Oncology June 2020 21(6):796-807
Subject
Language
ISSN
1470-2045